Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults

Inclusion Criteria: * Healthy male and female volunteers, 18-60 years * Seronegative for one or two of the applied vaccine strains * Low antibody titres for H1N1v * Written informed consent to participate in this study * For female volunteers of childbearing potential, provision of a history and current use of reliable contraceptive practices Exclusion Criteria: * Acute febrile illness (\>37.3°C) * Signs of acute or chronic upper or lower tract respiratory illnesses * History of severe atopy * Seasonal influenza vaccination in 2008/2009 and/or later seasons and/or pandemic influenza vaccination at any time * Fever ≥38.0°C in the time period between the pre-screening visit and day 1 * Known increased tendency of nose bleeding * Volunteers with clinically relevant abnormal paranasal anatomy * Volunteers with clinically relevant abnormal laboratory values * In female volunteers of childbearing potential, a positive urine pregnancy test * Simultaneous treatment with immunosuppressive drugs incl. Corticosteroids (≥2 weeks) within 4 weeks prior to study medication application * Clinically relevant history of renal, hepatic, GI, cardiovascular, haematological, skin, endocrine, neurological or immunological diseases * History of leukaemia or cancer * HIV or Hepatitis B or C seropositivity * Volunteers who underwent rhino or sinus surgery, or surgery of another traumatic injury of the nose within 30 days prior to application of study medication * Volunteers who have received antiviral drugs, treatment with immunoglobulins or blood transfusions, or an investigational drug within 4 weeks prior to study medication application * Volunteers who have received anti-inflammatory drugs 2 days prior to study medication application * Volunteers who are not likely to cope with the requirements of the study or with a significant physical or mental condition that may interfere with the completion of the study